Metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease risk: Dual aetiology or metabolic dysfunction?

被引：1
作者：
Ma, Tianyi [1 ]
Yuan, Huawei [1 ]
Guo, Zhanfang [1 ]
机构：
[1] Dalian Univ Technol, Cent Hosp, Dept Gastroenterol & Hepatol, Dalian, Peoples R China
来源：
LIVER INTERNATIONAL | 2024年 / 44卷 / 11期
关键词：
D O I：
10.1111/liv.16082
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：3103 / 3104
页数：2
相关论文
共 50 条
  • [31] Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Shi, Yiwen
    Fan, Jiangao
    [J]. CHINESE MEDICAL JOURNAL, 2022, 135 (09) : 1009 - 1018
  • [32] The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease
    Goya, Takeshi
    Imoto, Koji
    Tashiro, Shigeki
    Aoyagi, Tomomi
    Takahashi, Motoi
    Kurokawa, Miho
    Suzuki, Hideo
    Tanaka, Masatake
    Kato, Masaki
    Kohjima, Motoyuki
    Ogawa, Yoshihiro
    [J]. GASTROENTEROLOGY INSIGHTS, 2022, 13 (01) : 20 - 26
  • [33] Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease
    Fouad, Yasser
    Alboraie, Mohamed
    Shiha, Gamal
    [J]. HEPATOLOGY INTERNATIONAL, 2024, 18 (SUPPL 2) : 827 - 833
  • [34] Risk scores for metabolic dysfunction-associated fatty liver disease in pediatric obesity
    Lischka, Julia
    Lieb, Katharina
    Schanzer, Andrea
    Hojreh, Azadeh
    Ba-Ssalamah, Ahmed
    de Gier, Charlotte
    Walleczek, Nina-Katharina
    Zeyda, Maximilian
    Greber-Platzer, Susanne
    [J]. ANNALS OF NUTRITION AND METABOLISM, 2022, 78 (05) : 247 - 254
  • [35] Risk Factors for the Development of Metabolic Dysfunction-Associated Fatty Liver Disease in Mexico
    Tellez, S.
    Lopez, G.
    Gonzalez, M.
    Contreras, R.
    [J]. ANNALS OF NUTRITION AND METABOLISM, 2024, 80 : 138 - 139
  • [36] Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers
    Liu, Zhenqiu
    Lin, Chunqing
    Suo, Chen
    Zhao, Renjia
    Jin, Li
    Zhang, Tiejun
    Chen, Xingdong
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2022, 127
  • [37] LIVERSTAT for risk stratification for patients with metabolic dysfunction-associated fatty liver disease
    Leow, Yong Wen
    Chan, Wah Loong
    Lai, Lee Lee
    Mustapha, Nik Raihan Nik
    Mahadeva, Sanjiv
    Quiambao, Ronald
    Munteanu, Mona
    Chan, Wah Kheong
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (10) : 2182 - 2189
  • [38] Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang
    Guo, Yanbo
    Yang, Jing
    Ma, Rulin
    Zhang, Xianghui
    Guo, Heng
    He, Jia
    Wang, Xinping
    Cao, Boyu
    Maimaitijiang, Remina
    Li, Yu
    Peng, Xinyu
    Zhang, Shijie
    Guo, Shuxia
    [J]. NUTRIENTS, 2022, 14 (12)
  • [39] Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
    Mellemkjaer, Anders
    Kjaer, Mikkel Breinholt
    Haldrup, David
    Gronbaek, Henning
    Thomsen, Karen Louise
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 28 - 34
  • [40] Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
    Lim, Soo
    Kim, Jin-Wook
    Targher, Giovanni
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2021, 32 (07) : 500 - 514
12345